@wipo.int #SCP37 Future work @jamielove.bsky.social @innovarte-ong.bsky.social @3rdworldnetwork.bsky.social

US: "The SCP’s mandate found in the document SCP/1/2 specifically refers to facilitating the, and I quote, progressive development of international Intellectual Property law and international harmonization, end of quote." #SCP37 @genevahealthfiles.bsky.social @jamielove.bsky.social

#SCP37 The United States of America: "The United States is unable to agree to the language precluding substantive patent law harmonization discussions in this Chair’s summary."

@jamielove.bsky.social presenting on a Proposal for an Optional Mechanism within PCT: The WIPO Social Purpose Licensing Incentive. @wipo.int #SCP37 @keiwashdc.bsky.social @innovarte-ong.bsky.social @unitaid.bsky.social

@innovarte-ong.bsky.social Incentivos para el Licenciamiento Voluntario y Socialmente Responsable #SCP37 featurring Innovarte, KEI, MPP, University of Michigan, INAPI, and South Centre. @wipo.int @unitaid.bsky.social

@jamielove.bsky.social "Should it be it be more tailored to specific areas like a different sui generis thing for drug development for example that would be for another area if you think a sui generis approach is in the cards down the road." #SCP37

James Love (KEI) at WIPO SCP37: "If AI wipes out the patent system, as one of the panelists suggested and you wanted to have a sui generis system, do you think it should be one size fits all or do you think it should be sector specific unlike the unitary system for patents? Should it be it be more tailored to specific areas like a different sui generis thing for drug development for example that would be for another area if you think a sui generis approach is in the cards down the road."

@keiwashdc.bsky.social "If AI wipes out the patent system, as one of the panelists suggested and you wanted to have a sui generis system, do you think it should be one size fits all or do you think it should be sector specific unlike the unitary system for patents? @wipo.int #SCP37

TWN: "Another example is that of Trikafta which is a medicine for the treatment of cystic fibrosis which cost around $320,000 per year which cannot be affordable for vast majority of CF patients living in the developing countries." #SCP37 @justtreatment.org

"We would like to take this opportunity to inform or mention two developments which in a way advance the access to medicines in the context of patents and public health. We think that that would be relevant. The first development is that on 17th of October the Supreme Court of India rejected the petition by Roche seeking an injunction on a medicine for the treatment of spinal muscular atrophy. The medicine was priced around $6,900 per bottle and adults require around three bottles per month for maintaining the efficacy of that medicine.So as a result of the rejection of the injunction resulted in the introduction of the generic version of this medicine in India.Now it is available for just $179 per bottle."

@wipo.int #SCP37 "The first development is that on 17th of October the Supreme Court of India rejected the petition by Roche seeking an injunction on a medicine for the treatment of spinal muscular atrophy." @3rdworldnetwork.bsky.social

Samoa at @wipo.int #SCP37 - "However, Samoa's concerns arises from the fact that most of the IP offices in our side of the world is only becoming aware of rights because of their interest in the recent Genetic Resources and Associated Traditional Knowledge Treaty."

Singapore: "We would like to thank the Secretariat for preparing SCP/37/5 and SCP/37/6 which are useful resources. AI is transforming industry at an unprecedented pace with the pharmaceutical industry being a prime example." @wipo.int #SCP37

The European Union at @who.int #IGWG3 and @wipo.int #SCP37

Draft Reference Document on the Exception Regarding Farmers’ and/or Breeders’ Use of Patented Inventions
www.wipo.int/edocs/mdocs/... @wipo.int #SCP37 @jamielove.bsky.social @manonress.bsky.social 2 October 2025

Timetable for @wipo.int #SCP37